The CBD Submarket Plays a Major Role in the Legal Cannabis Industry

Tuesday, April 4, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 3, 2017 /PRNewswire/ -- News Commentary 


major submarket of the legal cannabis industry is Cannabidiol (CBD). CBD is the part of the plant that is not associated with the side effects of THC, so therefore CBD is usually used for medical reasons and not reactional purposes. A report by The Hemp
Business Journal projects that the CBD market will reach $2.1 billion in consumer sales by 2020, with $450 million of those sales coming from hemp-based sources. The report reveals that in 2015, the market for hemp-derived CBD products was worth $90 million. The addition of the $112 million in marijuana-derived CBD products were sold through dispensaries and the total CBD market was worth $202 million in 2015., Inc. (OTC: CIIX), Medicine Man Technologies Inc. (OTC: MDCL), CV Sciences, Inc. (OTC: CVSI), Cannabis Sativa, Inc. (OTC: CBDS), Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)

Others have similar or more optimistic estimates about the industry's future. Matt Karnes from Greenwave Advisors stated, "In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only - this is in addition to the 28 states plus DC that have legalized medical marijuana." A report by Forbes points out there is evidence that traditional cannabis users are willing to give CBD a try. Outco, the largest licensed cultivator in Southern California published data that shows 38% of users and non-users claimed they wanted to learn more about CBD oil., Inc. (OTCQB: CIIX) is a premier financial information website for Chinese-speaking investors. On March 30th the company announced its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company. Building on the success that CIIX enjoyed through its investment in early-stage firm Medicine Man Technologies, the Company is pleased to announce another strategic investment in the cannabis industry.

Breakwater MB was formed by CIIX board member and former CFO Paul Dickman as a means to invest capital in and provide consulting services to private, cannabis-focused companies as they transition into the public market. The invested capital will primarily be used to cover the costs of becoming a publicly-traded company, a strategy CIIX expects will provide significant investment appreciation and opportunity for liquidity. All opportunities will be evaluated by the investment committee comprised of CIIX CEO Warren Wang, Medicine Man Technologies Inc. (OTCQB: MDCL) CEO Andy Williams, and Paul Dickman, the CFO of Medicine Man and managing member of Breakwater MB.

"By focusing on these transitional phase investments, it's our expectation that investors in Breakwater MB will enjoy significant capital appreciation in its investment due to the arbitrage in value between private and public companies, the growth through access to the capital markets, the firm's expertise and established network, as well as short-term liquidity due to investing in newly formed publicly traded companies," states Dickman.

CV Sciences, Inc. (OTCQB: CVSI) is a supplier and manufacturer of hemp-derived CBD oil. The company recently announced its industry dominating brand of hemp-derived CBD oil finished products; PlusCBD Oil™ will be exhibiting at Natural Products Expo West on March 9-12, in Anaheim, California. Produced by New Hope Network, Natural Products Expo West is one of the world's leading trade shows in the natural, organic and healthy products industry attracting over 77,000 industry professionals and 3,000 exhibits to the Anaheim Convention Center. "As the preeminent leaders in hemp-derived CBD, we believe it is our obligation to create products that retailers can count on," stated Stuart Tomc, VP of Human Nutrition and spokesperson at CV Sciences. "PlusCBD Oil™ has been driving the growth of this newly emerging category due to the consistency, efficacy, and safety profile of our products. We are pleased to report that PlusCBD Oil™ is now available in over 1000 health food stores and counting, and we truly have our retailer partners to thank for joining the CBD Evolution - many of whom have been with us since our first Expo West two years ago."

Cannabis Sativa, Inc. (OTCQB: CBDS) develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The company announced that on December 20, 2016, the company's subsidiary was awarded Patent PP27,475 for a Cannabis Plant named Ecuadorian Sativa and deemed "CTA". Equadorian Sativa has been shown in laboratory testing by Steephill Labs to have a Limonene level that is extraordinarily high at a level of 4.53, 10 to 20 times the usual range. This sets Equadorian Sativa apart from other varieties in its odor, the effects on mood and mentation and its medical qualities.

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases. Earlier in January, the company announced that the European Commission has granted Orphan Designation in the European Union ("EU") for the Company's novel synthetic oral endocannabinoid-mimetic drug, JBT-101 ("Resunab") for the treatment of systemic sclerosis. A main endocannabinoid is 2-Arachidonoylglycerol (2-AG) which is active at both cannabinoid receptors, along with its own mimetic phytocannabinoid, CBD. 2-AG and CBD are involved in the regulation of appetite, immune system functions and pain management.

Please sign up now at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially-driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, expects to be compensated three thousand dollars for financial news dissemination and pr services by inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a two year agreement with inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store